EU JCA 2025 Explained: What Rare Disease Sponsors Need to Know Now
The EU Joint Clinical Assessment (JCA) is one of the most significant changes to hit market access in years.[…]
Patient experience data is now core evidence for the Joint Clinical Assessment
The EMA’s Reflection Paper published in September 2025 confirms an important shift. Patient experience data is no[…]
JCA is underway…what it really means for rare disease evidence
Introduction This article first appeared in the Rare Focus newsletter on LinkedIn (October 2025). The EU Joint Clinical[…]